Tuesday, 28 April 2015

Essay-Competition-cum Young Scholar’s Seminar on "The Idea of India"

Indian Council of Philosophical Research organizes Essay-Competition-cum Young Scholar’s Seminar on "The Idea of India".

In order to encourage the Young Scholars of the country to reflect on Philosophical issues, the Council holds an Essay Competition-cum-seminar every year. This year, the theme of the Competition is “The Idea of India”.

Young scholars in the age group of 20-25 years (born between 31.7.1990 to 31.7.1995) may send their essays typed in English or Hindi consisting of about 3000 words on one side of 21X30 cm. Size paper on the above theme.

Topic:                                       The Idea of India.

Last date for submission:          31st July 2015.
Submissions to:                  

The Programme Officer

Academic Centre

Indian Council of Philosophical Research

3/9, Vipul Khand, Gomti Nagar, Lucknow-226010.

Prizes:                                         First Prize - Rs. 25,000

Second Prize - Rs. 20,000

Third Prize - Rs. 15,000

Details:           www.icpr.in/Essay%20Competition%20for%20Young%20Scholars.pdf

On the basis of evaluation, 25-35 competitors will be invited to participate in a seminar to be organized by the Council. The competitors shall present their papers in the seminar and take part in the discussion on the papers. The final award shall be decided on the basis of the quality of the essay and the participation in the seminar.

The ICPR will make arrangements for the boarding and lodging for the young Scholars participating in the seminar.

Friday, 24 April 2015

Pharma academic research - Indian patent applications published on 24th April 2015

Dear All,

Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.
We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes.
For details of these patents, please write back to us at pharmaliterati@gmail.com
Indian patent applications published on 24th April 2015

Application No
Sustained release pharmaceutical compositions of Losartan potassium and
Process for preparation thereof
1)Pawar Harshal Ashok
 2)Lalitha K.G.
Not Known
Formulation and evaluation of Itraconazole loaded Niosomal gel for the
treatment of onychomycosis
1)Sahil Nagpal
 2)Dr. Amit Goyal
 3)Dr. Raj Kumar Narang
I.S.F. College of Pharmacy,
FZR G T Road, Moga (Punjab) India
Preparation, evaluation and characterization of a formulation for its
Photoprotective and radio decontamination activity
1)Sandeep Sharma
 2)Sudha Rana
 3)Tanmay M
 4)Arti Thakkar
 5)Rakesh Kumar Sharma
 6)R.S.R Murthy
I.S.F. College of Pharmacy,
FZR G T Road, Moga (Punjab) India
A Novel Composition For Arthritis
1)DR. Syed Tanvir Ali
 2)Gurmukh Singh Ghuldu
Not Known

Merck Collaborates with Maharashtra University- CME tour in ten medical colleges in Nagpur, Yavatmal, Akola, Latur, Nanded, Aurangabab, Pune, Mirag and Kolhapur in February, March and April as a first stage in India

Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, in collaboration with Maharashtra University of Health Sciences and Directorate of Medical Education & Research is introducing European Accredited Clinical Diabetes management for more than 5000 medical students in 18 medical colleges of Maharashtra University as part of Merck Capacity Advancement Program (CAP) in Asia.
The course is European accredited and will be incorporated in the MBBS curricula of 18 medical colleges. It is aimed to build up the future Diabetes health care capacity in Maharashtra.

Prof. Dr Arun Jamkar, Vice Chancellor of Maharashtra University of Health Sciences, MUHS- Nashik emphasized" It gives us immense pleasure to invite the stakeholders in the field of medicine and diabetes in Maharashtra In joint collaboration with DMER and Merck, this Diabetes education course aims to provide guidelines and clinical practice for prevention, diagnosis and management of diabetes and its complications for medical undergraduates of the 18 medical colleges in Maharashtra university."
The 5 year program was kicked off successfully in 7 sub- Saharan countries which are Kenya, Uganda, Namibia Angola, Ghana, Tanzania and Mozambique and will further expand to other Sub-Saharan and Asian countries in 2014.

Based on its long experience in diabetes management, which began in 1957 with the development of metformin, Merck seeks to raise awareness of diabetes in India by educating the public and supporting the healthcare system to prevent, diagnose and manage the condition effectively.

As part of the Merck Capacity Advancement Program- CAP, by end of 2015, more than 5,000 medical students in partnership with  African universities such as University of Nairobi, Makerere University, Namibia University and University of Ghana, in addition to Asian universities such as  Maharashtra University in India and University of Indonesia will benefit from European-accredited clinical diabetes and chronic diseases management training, which is seeking to equip them with skills to avert the diabetes and hypertension epidemic. Merck is planning to target more than 15,000 students by the end of 2018 expanding to more African, Asian, Latin American and Middle Eastern countries with special focus on non -communicable diseases such as Diabetes, Cancer, Thyroid Dysfunction and Fertility management. The program also focuses on building research capacity and improving supply chain in order to improve patient safety in Africa.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of our customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

For full info click here

Wednesday, 22 April 2015

IPA Convention 2015

Indian Pharmaceutical Association is organizing its annual Convention this year in Mumbai at Hotel Trident, BKC, Mumbai.  
The details are as follows:
Theme:                  Indian Pharma Inc: Adapting to the Rapidly Evolving Global Challenges.
Dates:                    5th - 6th June 2015.
Organized by:        Indian Pharmaceutical Association. 
Location:                Mumbai.
Available at: http://www.ipapharma.org/events/IPA%20Convention%202015%201st%20Flyer.pdf

The details would be posted soon on the website http://www.ipapharma.org/.

Tuesday, 21 April 2015

Workshop on Laboratory Data Integrity

The Indian Drug Manufacturers’ Association and the above IDMA Subcommittees have pleasure in announcing the first Workshop of 2015 on ‘Laboratory Data Integrity’.
This workshop will allow the delegates to receive hands-on information regarding the “Do’s and Don’ts” of Data Integrity from experts in the field. At this workshop, Eminent Technical personnel from the Indian Pharmaceutical Industry, Research, Academic and Regulatory Affairs will converge and get together to interact on the various issues faced with regard to Laboratory Data Integrity.
The details are as follows:
Theme:                       Workshop on Laboratory Data Integrity.
Dates:                         8th May 2015.
Organized by:           IDMA. 
Location:                    Mumbai.
Details available at: http://www.idma-assn.org/

1000 generic medicine stores to be opened in June

Indian Express reports that over 1000 stores selling generic medicines will be opened across India in June this year, when the government launches the scheme to provide affordable medicines, said Hansraj Ahir, Union Minister of State for Chemicals & Fertilizers on Monday.
“We are planning to launch in June….Over 1000 stores will be opened in the first month. We have a target of opening 3000 generic medicine shops during this year,” said Ahir who was in Ahmedabad to attend a workshop on Good Manufacturing Practices for the Indian Pharmaceutical manufacturers and state regulators.
“The government is also planning to rope in both the private sector and public sector units to help in providing uninterrupted supply of generic medicines to these new stores,” Ahir said adding that the government will start off with 504 medicines and then scale it over 670 medicines.
According to the minister, the government is ensuring that the new generic stores will be handed over to unemployed youths who have either a diploma or a graduation in pharmacy.
“We will ensure that these stores are run by unemployed youths and they sell only generic drugs,” Ahir said adding that the first set of stores will be opened at district level public hospitals and medical colleges.
Apart from generic medicine shops, the government is also looking to revive sick pharma central PSUs (Public Sector Units). “The revival of these PSUs will be done through a self-financing model,” said Sudhansh Pant, joint secretary, Department of Pharmaceuticals.
“A portion of the land holdings held by these PSUs will be sold off and the money generated will be used to finance these units. This will thus not require any budgetary support or financial assistance from the government,” Pant added.
The government will be using this self-financing model to revive sick drug manufacturing units like Indian Drugs Pharmaceuticals Ltd (IDPL), Hindustan Antibiotics and Bengal Chemicals.

Generic drugs_2 articles from Kashmir

Maha Darakshan discusses the hot debate in her article entitled "Generics versus Research" which can be accessed at http://www.risingkashmir.com/generics-versus-research/.
The article focuses on the harsh realities in Indian Pharmaceutical market and the way the business is carried out. The debate as rightly pointed out by the author should be  primarily focused on ‘quality versus substandard’ pharmaceutical products.
Another article by Dr. Geer Mohammad Ishaq, Senior Assistant Professor, Department of Pharmaceutical Sciences, University of Kashmir is about generic drug prescribing, which can be accessed at http://www.greaterkashmir.com/news/2015/Apr/15/generic-drug-prescribing-7.asp
The article presents the current pharmacy practice in Kashmir. The highlight of the article is reproduced below:
"It is saddening that even after fifteen years of formation of our own J&K Pharmacy Council which is not an offshoot of Pharmacy Council of India unlike other states, we don’t have qualified and trained pharmacy graduates working as pharmacists either in government or in private sector. In government hospitals Medical Assistants with one year multi-purpose health worker type diploma in their hands are employed as pharmacists whereas in private sector matriculates with some experience in sale of medicines at a retail counter have been registered as pharmacists and granted drug sale licenses as per a redundant and obsolete piece of legislation known as the J&K Pharmacy Act, 2011 (samvat) that has been framed more than sixty years back and amended only once to include matriculates as registered pharmacists. Consequently patients are deprived of good counseling services on the use of medicines." 


New data backs 'pulsatile' statin dosing

Pharma Times reports that new research suggests that pulsatile - or intermittent - dosing of statins might be effective enough to maintain an adequate cholesterol-lowering effect, while offering the advantages of boosting treatment compliance and cutting back National Health Service costs.
An analysis of UK GP prescribing and test records, sponsored by the SEEK Group, has shown that cholesterol levels remain below pre-statin levels for several months after patients stop taking them, raising hopes that their benefit could be reaped with just one week of dosing every three months instead of the current daily regime. 
In the UK seven million people are currently taking statins to cut cholesterol, but treatment compliance and persistence is poor. Side effects include nosebleeds, sore throat, muscle weakness, problems with the digestive system, and an increased risk of diabetes, and more than 50% of patients stop their statin therapy within a year, worsening treatment outcomes.
“If we have an opportunity to increase compliance and minimise these drug side-effects for our patients, without reducing the undoubted benefit of statins, we should certainly take it”, noted Professor John Deanfield, British Heart Foundation Professor of Cardiology at University College London, Consultant Cardiologist at Great Ormond Street Hospital and the Heart Hospital.
Given the limitations of observational data, the researchers now intend to run a full ‘interventional’ clinical trial, which they hope will prove that interrupted statin dosing is a viable way of maintaining low cholesterol. The study is scheduled to being in the last quarter of this year.

Pharma MBA Courses & the growing need of talented managers

Responding to the requirement of pharmaceutical industry and the recent development in pharma education, healthcare research institutions of the country, The IIHMR (Indian Institute of Health Management and Research) University invites applications for MBA in Pharmaceutical Management.
As per Mc Kinsey report-India Pharma 2015 – Unlocking the Potential of the Indian Pharmaceutical Market, the pharma industry has immense opportunities and has a projected market growth of USD 24 billion by 2015 and USD 55 billion by 2020. 

The hospital segment will increase its share and influence, growing to 25 per cent of the market in 2020. Forecasting the growth factors and the employment opportunities that will rise to over 4 million by 2025, 
As per the PwC study Indian Pharma Inc. the industry is likely to be in the top ten global markets in value terms by 2020.” There is a growing need of talent pool and it is indeed a growing challenge for the academia, to transform the students into management professionals.

Placement partners at IIHMR have also motivated us to generate best of the talents that has been recognised by domestic and global organisations.” To launch out the desired resources for the pharma industry, The IIHMR University offers a support system that ensures a focused involvement of both academia and industry. As an academic institution, The IIHMR University has systems and procedures to ensure that industry expectations are met without any compromise on academic aspirations. 
Besides IIHMR, MBA in Pharmaceutical Management is also offered by the following institutes.

Name of Institute
Name of Course
NIPER, Mohali, Punjab
Pharmaceutical Management; M.B.A.(Pharm.)
 (Page 5)
Manipal, Uddapi, Karnataka
MBA Pharmaceutical Management
NMIMS, Mumbai, Maharashtra
MBA (Pharmaceutical Management)
Punjab University Chandigarh
MBA Healthcare Management
SIES College of Management Studies, Navi Mumbai
Post Graduate Diploma in Pharmaceutical Management
PGDM (Pharmaceutical Management)

Institute Of Pharmaceutical and Healthcare Management, Kolkata
Executive Post-Graduate Diploma in Pharmaceutical Management 
IIMR Pharma Business School, Delhi
Various courses are offered
Indian Institute of Commerce & Trade, Lucknow
MBA Dual Specialization
MITCON Institute of Management, Pune
PGDM Pharmaceutical Management
Institute of clinical research ,Indiranagar, Bangalore
MBA in Healthcare Management
MBA in Pharma Marketing & Management
D.Y. Patil University
School of Management, Navi Mumbai
MBA in Pharmaceutical Industry Management
Amity Business School, Gurgaon (Manesar)
MBA (Hospital & Healthcare Management)

Also, please find the Mc Kinsey report-India Pharma 2015 & 2020 here and here